EVALUATION STUDIES
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI.

PURPOSE: We investigated whether the gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI was useful for nonalcoholic steatohepatitis (NASH) staging based on the severity of liver fibrosis.

MATERIALS AND METHODS: Twenty-one male Sprague-Dawley rats aged 7 weeks, weighing about 150g in NASH group were fed a choline-deficient diet for 4, 7 or 10 weeks, and seven rats in the control group were fed a standard diet (n=7). After the feeding period, the rats were subjected to contrast-enhanced MRI (2D-FLASH; TR/TE=101/2.9ms, flip angle 90 degrees ). Gd-DTPA (0.1mmol Gd/kg) and Gd-EOB-DTPA (0.025mmol Gd/kg) were injected at 24-h intervals, and the speed of contrast injection was 1mL/s. Signal intensities of the liver were measured and the relative enhancement (RE), the time of maximum RE (T(max)) and elimination half-life of RE (T(1/2)) in the liver were compared. The fibrosis rate (%) was calculated with the following formula: fibrosis/whole areax100.

RESULTS: The fibrosis rates of each group were as follows: 0.52, 0.79, 2.84, and 0.50% (4, 7, 10 weeks and control groups). The fibrosis rate of the 10 weeks group was significantly higher than the control and 4 or 7 weeks groups. Although there was no difference between the T(max) and T(1/2) of each group after Gd-DTPA injection, the T(max) and T(1/2) of the 10 weeks group were significantly prolonged in comparison with the control and 4 or 7 weeks groups after Gd-EOB-DTPA injection (p<0.01). There was a significant correlation between the fibrosis rate and T(max) or T(1/2) after Gd-EOB-DTPA injection (r=0.90 or 0.97).

CONCLUSION: It was possible to assess the progress of liver fibrosis in NASH by evaluating the signal intensity-time course on Gd-EOB-DTPA-enhanced MRI.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app